Filing Flows › Lenz Therapeutics (LENZ) › Q2 2026 › vs Q1 2026
Lenz Therapeutics (LENZ) Q2 2026 vs Q1 2026 (quarter over quarter)
Lenz Therapeutics's revenue rose $3.6M (+189%) from $1.9M in Q1 2026 to $5.5M in Q2 2026. The biggest changes: License revenue +$3.5M (15×); Product sales, net +$85K (+5%).
Lenz Therapeutics, Q2 2026: revenue $5.5M (+10% year over year), operating margin -622.9%, net loss $31.9M, operating cash flow −$38.7M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| License revenue | $3.8M | $250K | $3.5M | 15× |
| Product sales, net | $1.7M | $1.7M | $85K | +5% |
| Revenue | $5.5M | $1.9M | $3.6M | +189% |
| Other income, net | $2.3M | $2.6M | −$390K | -15% |
| Net loss | $31.9M | $41.5M | −$9.6M | -23% |
| Costs & expenses | $39.7M | $46.0M | −$6.4M | -14% |
| Operating costs | $39.7M | $46.0M | −$6.4M | -14% |
| Income tax | $3K | $0 | $3K | — |
| Cost of revenue | $280K | $1.1M | −$796K | -74% |
| SG&A | $39.4M | $45.0M | −$5.6M | -12% |
| Operating cash sources | $43.3M | $38.0M | $5.3M | +14% |
| Depreciation & amortization | $110K | $111K | −$1K | -0.9% |
| Share-based compensation | $4.5M | $4.3M | $153K | +4% |
| Cash used in operations | $38.7M | $33.6M | $5.1M | +15% |
| Net loss absorbed | $31.9M | $41.5M | −$9.6M | -23% |
| Working capital & other | $11.4M | −$3.5M | $14.9M | — |
Questions
How much did Lenz Therapeutics's revenue grow quarter over quarter in Q2 2026?
Lenz Therapeutics's revenue rose $3.6M (+189%) from $1.9M in Q1 2026 to $5.5M in Q2 2026.
What drove Lenz Therapeutics's revenue change in Q2 2026?
License revenue +$3.5M (15×); Product sales, net +$85K (+5%).